Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Am J Clin Dermatol
; 25(4): 685-688, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38802618
Full text:
1
Database:
MEDLINE
Main subject:
Psoriasis
/
Dermatologic Agents
/
Interleukin-23
/
Drug Substitution
/
Ustekinumab
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2024
Type:
Article